| P/E (FY) | — | Sales (TTM) | $127.5M |
| Earnings (TTM) | -$46.6M | ROE | −13.99% |
| Net Margin | −28.96% | ROIC | −83.15% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 40.00% |
RxSight is a commercial-stage medical technology company that researches, develops, manufactures, and sells light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. Its RxSight system lets doctors customize visual acuity after surgery and includes the Light Adjustable Lens, made of photosensitive material that changes shape under ultraviolet light, and a light delivery device that applies programmed UV patterns. The company was formerly known as Calhoun Vision.
| Market Cap | $250.4M | Trading Days | 1247 |
| 52W High | 13.22 |
| 52W Low | 4.48 |
| % Off High | −54.24% |
| YTD | −41.94% | 1Y | −23.13% |
| 3Y | −81.85% | Since incept. (ann.) | −19.02% |
Rxlal 80% · LDD 15% · Service Warranty Service Contracts And Accessories 4%
| Ann. Volatility (1Y) | 65.69% | Ann. Volatility (3Y) | 65.89% |
| Sharpe (1Y) | −0.08 | Sharpe (3Y) | −0.51 |
| Max Drawdown (1Y) | −64.94% | Max Drawdown (3Y) | −92.86% |
| Beta (3Y, vs SPY) | 1.99 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| STAA | STAAR SURGICAL CO | $1.12B | — |
| EYE | National Vision Holdings, Inc. | $1.75B | 58.9 |
| WRBY | Warby Parker Inc. | $2.81B | 2486.0 |
| BLCO | Bausch & Lomb Corp | $5.92B | — |
| LUCY | Innovative Eyewear Inc | $4.7M | — |
| COO | COOPER COMPANIES, INC. | $14.05B | 38.5 |
| ALC | Alcon Inc | — | — |
| FULC | Fulcrum Therapeutics, Inc. | $247.9M | — |
| MREO | Mereo BioPharma Group plc | $246.9M | — |
| MGNX | MACROGENICS INC | $244.7M | — |
| EDIT | Editas Medicine, Inc. | $256.5M | — |
| HNSA.ST |
| Hansa Biopharma AB |
| $244.3M |
| — |